CD28 and neoplasm: These results suggest that although the CD28 costimulatory domain functions more potently than 4-1BB in activating MET-CAR-T cells, it also acts more in exacerbating MET-CAR-T cell exhaustion, resulting in reduced expansion, persistence and anti-tumor activity.